IP Library › Granted Patent US 10,406,242
Granted Patent B2
US 10,406,242 · App. 15/830,736 · Granted Sep 10, 2019

Magnetic cells for localizing delivery and tissue repair

Inventors: Jeffrey L. Goldberg (Menlo Park, CA); Alan Halpern (Kalamazoo, MI)
Assignee: Emmetrope, Inc.
A61K47/6929A61K9/0034A61K9/0048A61K9/5094A61K35/28A61K35/30A61K35/44A61K41/00A61K47/68A61K47/6803A61K47/6829A61K47/6901A61K47/6923A61K47/6931A61N2/002A61K9/5115A61K35/12C12N5/0006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,406,242
App. No.
15/830,736
Granted
Sep 10, 2019
Kind
B2
Abstract

Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. for treatment of disease and/or injury.

Claims (18)

1. A method of delivering a cell to a target tissue in an animal, said method comprising,

(a) affixing, binding, or attaching at least one magnetic nanoparticle(s) to the surface of said cell to obtain a magnetic particle-comprising cell;

(b) administering said magnetic particle-comprising cell to target tissue in the animal;

(c) applying a magnetic field to said target tissue such that said magnetic particle-comprising cell is delivered to and held in place at specific regions of said target tissue, wherein the cell is a smooth muscle cell; and

(d) maintaining said magnetic field over said target tissue to cause said cell to remain at the target tissue.

2. The method of claim 1 , wherein the magnetic particle is affixed to the cell surface by means of a cell-surface specific binding agent.

3. The method of claim 1 wherein the magnetic particles have a mean diameter of no more than 500 nm.

4. The method of claim 3 wherein the magnetic particles have a mean diameter of no more than 200 nm.

5. The method of claim 1 wherein the magnetic particles comprise iron in any ferromagnetic form.

6. The method of claim 1 wherein the magnetic nanoparticles have a surface coating.

7. The method of claim 6 wherein the surface coating allows the binding of an antibody, antibody fragment, protein or sugar fragment that binds to cells.

8. The method of claim 1 wherein the magnetic particle comprising cells are administered by injection, infusion or surface application.

9. The method of claim 1 wherein the animal is a mammal.

10. The method of claim 9 wherein the mammal is a human.

11. A normal or genetically modified cell having a magnetic nanoparticle with a diameter of no more than about 500 nm bound to its surface covalently, or by a surface coating on the magnetic nanoparticle that binds the cell, and wherein the cell is a smooth muscle cell.

12. The cell of claim 11 wherein the magnetic particle has a diameter of less than 200 nm.

13. The cell of claim 11 wherein the magnetic particle comprises iron in any ferromagnetic form, with or without an inert surface coating, and wherein its surface allows the binding of a protein or sugar fragment that binds to cells.

14. A normal or genetically modified cell having a magnetic nanoparticle with a diameter of no more than about 500 nm bound to its surface covalently or by antibody-antigen linkage, wherein the cell is a smooth muscle cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2018
From: GOLDBERG, JEFFREY L.; HALPERN, ALAN
To: EMMETROPE INC.
Reel/Frame 045051/0531 →
Continuity (4)
Continuation 14797829 · Jul 13, 2015
Continuation 12866004
Provisional Application 61006861 · Feb 4, 2008
Related Publication 20180154021A1 · Jun 7, 2018
Cited By (1)
US 12,678,276